RxDoctor Payments Data

Neeti Alapati, MD

Glaucoma Specialist · Lenexa, KSNPI 1124327671

Payments from drug & device makers

$4,182in general payments, 2019–2025

Across 108 payments — averaging $38.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$973
  • Glaukos Corporation$619
  • Sun Pharmaceutical Industries Inc.$361
  • Sight Sciences, Inc.$223
  • NEW World Medical,inc.$162
  • plus $483 from 13 others

What the payments were for

  • Food & beverage$4,182100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$47,798
Medicare patients
151
Services billed
434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost108$47,687
CombiganBrimonidine Tartrate/Timolol97$25,019
SimbrinzaBrinzolamide/Brimonidine Tart21$8,621
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol48$8,149
Travoprost56$7,233
Latanoprost483$6,074
Alphagan PBrimonidine Tartrate26$5,356
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat190$3,661
Prednisolone Acetate64$3,524
Timolol Maleate217$3,266
Brimonidine Tartrate135$1,677
Dorzolamide Hcl68$1,428
Ketorolac Tromethamine20$358
MoxifloxacinMoxifloxacin Hcl12$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$973$78,062231 claims
AlconSimbrinza$1,361$8,62121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Kansason file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Lenexa

Where these figures come from

Is this you, or does something look wrong? →